Ipragliflozin (L-Proline)

• CAT Number: I019898
• CAS Number: 951382-34-6
• Molecular Formula: C₂₆H₃₀FNO₇S
• Molecular Weight: 519.58
• Purity: ≥95%
• Target: SGLT
• IUPAC Name: (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol;(2S)-pyrrolidine-2-carboxylic acid
• InChI: InChI=1S/C21H21FO5S.C5H9NO2/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14;7-5(8)4-2-1-3-6-4/h1-8,16,18-21,23-26H,9-10H2;4,6H,1-3H2,(H,7,8)/t16-,18-,19+,20-,21+;4-/m10/s1
• InChIKey: TUVGWWULBZIUBS-FVYIYGEMSA-N
• SMILES: C1C[C@H](NC1)C(=O)O.C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)F

Ipragliflozin (L-Proline)(CAT: I019898) is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor used extensively in metabolic disease research. By targeting SGLT2 in the renal proximal tubules, it reduces glucose reabsorption and promotes glycosuria, aiding in studies on type 2 diabetes mellitus and related metabolic disorders. The inclusion of L-proline enhances the compound’s pharmacokinetic properties, improving stability and solubility. With its high purity and specific activity, Ipragliflozin (L-Proline) is suitable for in vitro and in vivo studies, providing a reliable tool for exploring glucose homeostasis, renal physiology, and potential therapeutic interventions for diabetes management.